A T Van Oosterom


Ontology type: schema:Person     


Person Info

NAME

A T

SURNAME

Van Oosterom

Publications in SciGraph latest 50 shown

  • 2011-07 Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2008-07 Intra-hepatic Mitomycin C bolus infusion in the treatment of extensive liver metastases of breast cancer in BREAST CANCER RESEARCH AND TREATMENT
  • 2008-02 A phase II trial of docetaxel (Taxotere®) as second-line chemotherapy in patients with metastatic breast cancer in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 2005-11 Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948) in BRITISH JOURNAL OF CANCER
  • 2005-04 Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2005-03 New guidelines to evaluate the response to treatment in solid tumors in BREAST CANCER
  • 2004-12 Differential protein expression profile in gastrointestinal stromal tumors in AMINO ACIDS
  • 2004-08 Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors in INVESTIGATIONAL NEW DRUGS
  • 2004-08 Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site in MODERN PATHOLOGY
  • 2004-06 A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours in BRITISH JOURNAL OF CANCER
  • 2003-12 Pharmacology of Anticancer Drugs in the Elderly Population in CLINICAL PHARMACOKINETICS
  • 2003-10 A phase II trial with rosiglitazone in liposarcoma patients in BRITISH JOURNAL OF CANCER
  • 2003-07 Imatinib Mesylate in GIST: profile report in DRUGS & THERAPY PERSPECTIVES
  • 2003-06 Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11 in BRITISH JOURNAL OF CANCER
  • 2003-05 Metastatic Soft Tissue Sarcoma in Adults in AMERICAN JOURNAL OF CANCER
  • 2003-03 Imatinib Mesylate in DRUGS
  • 2002-02 Population Pharmacokinetic and Dynamic Analysis of the Topoisomerase I Inhibitor Lurtotecan in Phase II Studies in INVESTIGATIONAL NEW DRUGS
  • 2001-04 Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum in CANCER GENE THERAPY
  • 2000-08 Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG) in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2000-02 A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study in BRITISH JOURNAL OF CANCER
  • 1999-07 Intravesical Drug Delivery in CLINICAL PHARMACOKINETICS
  • 1999 Chemotherapy for Seminoma in CARCINOMA OF THE KIDNEY AND TESTIS, AND RARE UROLOGIC MALIGNANCIES
  • 1999 Is a Policy of Surveillance Warranted in Early Stage Testicular Cancer Following Orchiectomy? in CARCINOMA OF THE KIDNEY AND TESTIS, AND RARE UROLOGIC MALIGNANCIES
  • 1998-12 Angiogenesis: possibilities for therapeutic interventions in INTERNATIONAL JOURNAL OF CLINICAL PHARMACY
  • 1998-11 Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance in BRITISH JOURNAL OF CANCER
  • 1998-06 Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer in BRITISH JOURNAL OF CANCER
  • 1998-01 Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients in BRITISH JOURNAL OF CANCER
  • 1998-01 Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours in BRITISH JOURNAL OF CANCER
  • 1997-11 Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer in BRITISH JOURNAL OF CANCER
  • 1997-07 Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients in BRITISH JOURNAL OF CANCER
  • 1997-02 Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer in BRITISH JOURNAL OF CANCER
  • 1997-01 Influence of investigator experience and microscopic field size on microvessel density in node-negative breast carcinoma in BREAST CANCER RESEARCH AND TREATMENT
  • 1997 The management of ovarian cancer in THE TEACHING CASES FROM ANNALS OF ONCOLOGY
  • 1996-11 High endothelial cell proliferation index and high microvessel density in vascular hotspots suggest an active angiogenic process in human colorectal adenocarcinomas in BRITISH JOURNAL OF CANCER
  • 1996-08 Deep cerebral invasion by basal cell carcinoma of the scalp in NEURORADIOLOGY
  • 1995-08 Prognostic value of bcl-2 expression in invasive breast cancer in BRITISH JOURNAL OF CANCER
  • 1995-07 Effects and systemic uptake of the new mitomycin C analogue KW-2149 in beagle dogs after intravesical administration in UROLITHIASIS
  • 1995-06 Phase I and pharmacokinetic study of KW-2149 given by 24 hours continuous infusion in INVESTIGATIONAL NEW DRUGS
  • 1995-02 Microvessel quantification in primary colorectal carcinoma: an immunohistochemical study in BRITISH JOURNAL OF CANCER
  • 1995-02 EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma in BRITISH JOURNAL OF CANCER
  • 1994-07 The effects of an ACTH (4–9) analogue on development of cisplatin neuropathy in testicular cancer: A randomized trial in JOURNAL OF NEUROLOGY
  • 1994 Systemic treatment of bladder cancer in CANCER TREATMENT AN UPDATE
  • 1993-10 In vitro and in vivo chemosensitizing effect of cyclosporin A on an intrinsic multidrug-resistant rat colon tumour in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 1993-09 Drug resistance in rat colon cancer cell lines is associated with minor changes in susceptibility to cytotoxic cells in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 1991-07 Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 1990 Vincristin, Bleomycin, Mitomycin-C und Cisplatin als neoadjuvante Therapie bei der Strahlentherapie von Hochrisikopatientinnen mit Plattenepithelkarzinom der Cervix uteri in THERAPIE DES ZERVIXKARZINOMS
  • 1988-10 Pharmacokinėtics of intravenous and oral cyclophosphamide in the presence of methotrexate and fluorouracil in INTERNATIONAL JOURNAL OF CLINICAL PHARMACY
  • 1988 In Vivo Cis-Diamminedichloroplatinum(II)-DNA Adduct Formation and Removal as Measured with Immunochemical Techniques in PLATINUM AND OTHER METAL COORDINATION COMPOUNDS IN CANCER CHEMOTHERAPY
  • 1988 Chemotherapy in Advanced Soft Tissue Sarcoma — The EORTC Experience in RECENT CONCEPTS IN SARCOMA TREATMENT
  • 1988 Adjuvant Treatment with Radiotherapy to the Lungs and/or Chemotherapy for Osteosarcoma of the Limbs in RECENT CONCEPTS IN SARCOMA TREATMENT
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/grid.7700.0", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.10419.3d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.5590.9", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.419481.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417893.0", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.5477.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.154185.c", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.433812.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.434691.d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.410404.5", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.10417.33", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.239578.2", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.411414.5", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417540.3", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.410569.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417079.c", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.240145.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.477522.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.1055.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.39382.33", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.5284.b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.418116.b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.5645.2", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.415720.5", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.14925.3b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.430814.a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.214458.e", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.416308.8", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.424926.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.62560.37", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.15485.3d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.415193.b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.239826.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.5596.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.16872.3a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.418936.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.55325.34", 
            "type": "Organization"
          }
        ], 
        "familyName": "Van Oosterom", 
        "givenName": "A T", 
        "id": "sg:person.0653245357.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653245357.14"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2019-03-07T15:17", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-researchers-20181010/20181011/dim_researchers/base/researchers_951.json", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.0653245357.14'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.0653245357.14'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.0653245357.14'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.0653245357.14'


     

    This table displays all metadata directly associated to this object as RDF triples.

    88 TRIPLES      10 PREDICATES      47 URIs      7 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:person.0653245357.14 schema:affiliation N722e2f2a5494487fa5c289a505fdcf14
    2 https://www.grid.ac/institutes/grid.10417.33
    3 https://www.grid.ac/institutes/grid.10419.3d
    4 https://www.grid.ac/institutes/grid.1055.1
    5 https://www.grid.ac/institutes/grid.14925.3b
    6 https://www.grid.ac/institutes/grid.154185.c
    7 https://www.grid.ac/institutes/grid.15485.3d
    8 https://www.grid.ac/institutes/grid.16872.3a
    9 https://www.grid.ac/institutes/grid.214458.e
    10 https://www.grid.ac/institutes/grid.239578.2
    11 https://www.grid.ac/institutes/grid.239826.4
    12 https://www.grid.ac/institutes/grid.240145.6
    13 https://www.grid.ac/institutes/grid.39382.33
    14 https://www.grid.ac/institutes/grid.410404.5
    15 https://www.grid.ac/institutes/grid.410569.f
    16 https://www.grid.ac/institutes/grid.411414.5
    17 https://www.grid.ac/institutes/grid.415193.b
    18 https://www.grid.ac/institutes/grid.415720.5
    19 https://www.grid.ac/institutes/grid.416308.8
    20 https://www.grid.ac/institutes/grid.417079.c
    21 https://www.grid.ac/institutes/grid.417540.3
    22 https://www.grid.ac/institutes/grid.417893.0
    23 https://www.grid.ac/institutes/grid.418116.b
    24 https://www.grid.ac/institutes/grid.418936.1
    25 https://www.grid.ac/institutes/grid.419481.1
    26 https://www.grid.ac/institutes/grid.424926.f
    27 https://www.grid.ac/institutes/grid.430814.a
    28 https://www.grid.ac/institutes/grid.433812.f
    29 https://www.grid.ac/institutes/grid.434691.d
    30 https://www.grid.ac/institutes/grid.477522.1
    31 https://www.grid.ac/institutes/grid.5284.b
    32 https://www.grid.ac/institutes/grid.5477.1
    33 https://www.grid.ac/institutes/grid.55325.34
    34 https://www.grid.ac/institutes/grid.5590.9
    35 https://www.grid.ac/institutes/grid.5596.f
    36 https://www.grid.ac/institutes/grid.5645.2
    37 https://www.grid.ac/institutes/grid.62560.37
    38 schema:familyName Van Oosterom
    39 schema:givenName A T
    40 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653245357.14
    41 schema:sdDatePublished 2019-03-07T15:17
    42 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    43 schema:sdPublisher N6c82ae182e9241008f3443b158f56fc2
    44 sgo:license sg:explorer/license/
    45 sgo:sdDataset persons
    46 rdf:type schema:Person
    47 N6c82ae182e9241008f3443b158f56fc2 schema:name Springer Nature - SN SciGraph project
    48 rdf:type schema:Organization
    49 N722e2f2a5494487fa5c289a505fdcf14 schema:affiliation https://www.grid.ac/institutes/grid.7700.0
    50 sgo:isCurrent true
    51 rdf:type schema:OrganizationRole
    52 https://www.grid.ac/institutes/grid.10417.33 schema:Organization
    53 https://www.grid.ac/institutes/grid.10419.3d schema:Organization
    54 https://www.grid.ac/institutes/grid.1055.1 schema:Organization
    55 https://www.grid.ac/institutes/grid.14925.3b schema:Organization
    56 https://www.grid.ac/institutes/grid.154185.c schema:Organization
    57 https://www.grid.ac/institutes/grid.15485.3d schema:Organization
    58 https://www.grid.ac/institutes/grid.16872.3a schema:Organization
    59 https://www.grid.ac/institutes/grid.214458.e schema:Organization
    60 https://www.grid.ac/institutes/grid.239578.2 schema:Organization
    61 https://www.grid.ac/institutes/grid.239826.4 schema:Organization
    62 https://www.grid.ac/institutes/grid.240145.6 schema:Organization
    63 https://www.grid.ac/institutes/grid.39382.33 schema:Organization
    64 https://www.grid.ac/institutes/grid.410404.5 schema:Organization
    65 https://www.grid.ac/institutes/grid.410569.f schema:Organization
    66 https://www.grid.ac/institutes/grid.411414.5 schema:Organization
    67 https://www.grid.ac/institutes/grid.415193.b schema:Organization
    68 https://www.grid.ac/institutes/grid.415720.5 schema:Organization
    69 https://www.grid.ac/institutes/grid.416308.8 schema:Organization
    70 https://www.grid.ac/institutes/grid.417079.c schema:Organization
    71 https://www.grid.ac/institutes/grid.417540.3 schema:Organization
    72 https://www.grid.ac/institutes/grid.417893.0 schema:Organization
    73 https://www.grid.ac/institutes/grid.418116.b schema:Organization
    74 https://www.grid.ac/institutes/grid.418936.1 schema:Organization
    75 https://www.grid.ac/institutes/grid.419481.1 schema:Organization
    76 https://www.grid.ac/institutes/grid.424926.f schema:Organization
    77 https://www.grid.ac/institutes/grid.430814.a schema:Organization
    78 https://www.grid.ac/institutes/grid.433812.f schema:Organization
    79 https://www.grid.ac/institutes/grid.434691.d schema:Organization
    80 https://www.grid.ac/institutes/grid.477522.1 schema:Organization
    81 https://www.grid.ac/institutes/grid.5284.b schema:Organization
    82 https://www.grid.ac/institutes/grid.5477.1 schema:Organization
    83 https://www.grid.ac/institutes/grid.55325.34 schema:Organization
    84 https://www.grid.ac/institutes/grid.5590.9 schema:Organization
    85 https://www.grid.ac/institutes/grid.5596.f schema:Organization
    86 https://www.grid.ac/institutes/grid.5645.2 schema:Organization
    87 https://www.grid.ac/institutes/grid.62560.37 schema:Organization
    88 https://www.grid.ac/institutes/grid.7700.0 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...